MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$62.28M, compared with -$21.57M a year earlier. Trailing-twelve-month EBITDA was -$148.59M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -40.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$62.28M-52.5% QoQ
- Last fiscal yearDec 2025
- -$86.72M-40.6% YoY
- LTMSep 2026
- -$148.59M-85.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -188.8% | +100.0% | +288.8 pp |
| 1 year | -40.6% | +100.0% | +140.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (86.72M) USD
- Year-over-year change
- -40.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (86.72M) | -40.6% |
| FY2024 | 2024-12-31 | (61.68M) | -90.3% |
| FY2023 | 2023-12-31 | (32.41M) | -26.1% |
| FY2022 | 2022-12-31 | (25.71M) | — |
EBITDA vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -85.2% is the 7th highest of 8, against a peer median of +63.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €259.93M EUR | +295.2% | — | 21.5% | |
| LTM Mar 2026 | $78.84M USD | +1391.3% | — | — | |
| LTM Mar 2026 | $46.13M USD | +1163.1% | — | 14.7% | |
| LTM Mar 2026 | -$46.12M USD | +63.6% | — | — | |
| LTM Mar 2026 | -$88.27M USD | +2.7% | — | 245200.0% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$148.59M USD | -85.2% | — | — |
KLRAKailera Therapeutics, Inc. | FY2025 | -$158.03M USD | — | — | — |
| LTM Sep 2026 | -$173.24M USD | -2.5% | — | 61.7% | |
| LTM Jun 2026 | -$534.34M USD | -212.4% | — | — | |
| Peer median (excluding MBX) | — | +63.6% | — | 41.6% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 248K |
| Gross Profit | 0 | 0 | 0 | (248K) |
| Gross Margin | — | — | — | — |
| Research & Development | 21.4M | 28.53M | 57.42M | 79.16M |
| Selling, General & Admin | 3.76M | 6.78M | 10.78M | 18.9M |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 98.06M |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| EBITDA | (25.71M) | (32.41M) | (61.68M) | (86.72M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (25.16M) | (35.31M) | (68.19M) | (98.06M) |
| Operating Margin | — | — | — | — |
| Interest Income | 372K | 2.75M | 6.27M | 11.08M |
| Interest Expense | 374K | 0 | 0 | 0 |
| Other Income / Expenses | (974K) | 2.75M | 6.27M | 11.08M |
| Income Before Tax | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.82) | (1.02) | (1.85) | (2.38) |
| EPS (Diluted) | (0.82) | (1.02) | (1.85) | (2.38) |
| Weighted Avg Shares | 31.85M | 31.85M | 33.39M | 36.51M |
| Weighted Avg Shares (Diluted) | 31.85M | 31.85M | 33.39M | 36.51M |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.